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Abstract
Background: Breast hypertrophy is associated with clinically important morbidity. A prospective
study was conducted to assess the change in health-related quality of life (HRQL) following breast
reduction mammoplasty. This paper describes the measurement properties of each of the HRQL
questionnaires used.
Methods: The reliability, responsiveness, and the construct validity of each HRQL instrument (the
Health Utilities Index Mark 2 (HUI2) and Mark 3 (HUI3) and the Breast Reduction Assessment
Value and Outcomes (BRAVO) instruments) were assessed. The BRAVO instruments are a set of
separate instruments including the Short Form-36 (SF-36), the Multidimensional Body Self Relations
Questionnaire Appearance Assessment (MBSRQ-AS), and the Breast Related Symptoms
Questionnaire (BRSQ).
Results: The HUI2, the HUI3, the MBSRQ-AS, and the breast severity symptom (BSS) score from
the BRSQ all demonstrated good test-retest reliability. The SF-36 physical component summary,
the MBSRQ-AS, and the BSS score demonstrated high responsiveness. The SF-36 mental
component summary and the HUI3 had a moderate effect size and the HUI2 had a small effect size.
All of the changes in scales are correlated in the same direction except for the SF-36 physical
component summary and the SF-36 mental component summary.
Conclusion: All four instruments were found to be reliable and responsive. These instruments
can be used in similar clinical settings to evaluate the change in patients' HRQL.
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Background
Within the last decade the plastic surgical community has
been encouraged to use health-related quality of life
(HRQL) assessment instruments to report on the efficacy
of surgical interventions [1-5]. There is also an increased
awareness of the impact of health and healthcare on the
quality of human life such as a patient's ability to perform
daily activities. Positive themes of happiness, social well-
being, and emotional well-being need to be measured as
these variables are particularly relevant to plastic surgery.
Various HRQL instruments, generic and disease or condi-
tion specific, have been applied to plastic surgery research,
especially in the area of breast hypertrophy and reduction
mammoplasty [6-19]. Evidence from other clinical set-
tings has shown that the generic instruments may be as
efficient as the disease-specific ones [20-22]. A recom-
mendation was made by Guyatt et al to include both a
generic and a disease (condition) specific instrument in
the evaluation of medical interventions [23].
Breast hypertrophy has been reported by patients to be
associated with important burdens in pain and discom-
fort as well as emotion [7]. Earlier breast studies used a
variety of study designs, instruments, and outcome meas-
ures [6-19]. These studies found that breast hypertrophy
was associated with significant morbidity and reduced
HRQL. They also found that after breast reduction mam-
moplasty patients had a substantial improvement in
HRQL. Kerrigan et al found that patients with breast
hypertrophy had lower health utility scores compared to
controls without breast hypertrophy [6]. In a second
report, Kerrigan et al found that patients with breast
hypertrophy scored lower on the EuroQol; McGill Pain
Questionnaire, Multidimensional Body Self Relations
Questionnaire (MBSRQ), Short Form 36 (SF-36), and
breast-related symptoms questionnaire (BRSQ) than the
controls [7]. A recent prospective study found that pre-
operatively mammoplasty patients scored lower on the
SF-36 compared to normative data and there was an
improvement in SF-36 scores from pre-operative to post-
operative and these improvements were maintained to 12
months [13]. The improvements noted after the reduction
mammoplasty remained stable at three years post-surgery
[14]. In a cohort study, Collins et al found that pre-surgery
patients scored significantly lower on the SF-36 than nor-
mative data and that following reduction mammoplasty
patients improved from pre-surgery in all eight domains
of the SF-36 [8]. Collins et al also found that post-surgery
pain was lower and that the benefits from breast reduction
were not associated with body weight, bra cup size, or
weight of tissue resection [8].
In a recent Canadian prospective study of patients with a
body mass index (BMI) below 27, pre-surgery mammo-
plasty patients scored lower on the SF-36 compared to
normative data and post-surgery these patients achieved
scores similar to normative data [18]. Although several
publications have addressed HRQL in patients with breast
hypertrophy, reduction mammoplasty remains a contro-
versial surgery because of the denial of insurance coverage
based on BMI in certain jurisdictions [18,19].
A number of different instruments have been used in pre-
vious studies to measure HRQL in patients with breast
hypertrophy. In terms of the hierarchy of evidence in sur-
gical studies, the studies which provide the higher
strength of evidence are prospective cohort studies which
address important patient outcomes. These studies have
shown an improvement from pre-operative to post-oper-
ative, which have been statistically significant. Our study
is similar to the design of some of the earlier prospective
cohort studies measuring HRQL in patients with breast
hypertrophy [8,10,13-15,18]. A recent study and discus-
sion by Kerrigan et al stresses the importance of measuring
HRQL and incorporating patient-reported health status
into everyday practice [18,24]. The current study is the
first to use the Health Utilities Index (HUI) as an outcome
assessment [25-28]. This study is also the first prospective
study to simultaneously assess the measurement proper-
ties of four HRQL instruments in breast reduction
patients.
The primary objective of this study is to look at the meas-
urement properties, including the reliability and respon-
siveness, of each of the four HRQL instruments used. The
secondary objective was to assess the concurrent validity
of each of the four HRQL instruments.
Methods
Patient eligibility and study design
Consecutive patients seen by the senior author (AT) over
a period of one-year, with the diagnosis of breast hyper-
trophy and who obtained government approval for reduc-
tion mammoplasty were invited to participate in this
prospective study. After signing an informed consent
form, patients were asked to complete several question-
naires at each assessment time: (one week (time one) and
one day before surgery (time two) and at one month
(time three), six months (time four), and 12 months after
surgery (time five)). The questionnaires were the HUI [25-
28], and the Breast Reduction Assessment Value and Out-
comes (BRAVO) instruments which consist of a set of sep-
arate instruments including the SF-36 [29], the MBSRQ-
AS [30], and the BRSQ [7,24]. The one-week recall period
was used for the HUI, the MBSRQ-AS, and the BRSQ and
a four-week recall period was used for the SF-36.
The patients were provided with the questionnaires at
their clinic visits and they either completed them while at
the clinic or they completed them at home and returnedHealth and Quality of Life Outcomes 2005, 3:44 http://www.hqlo.com/content/3/1/44
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them to the clinic by mail. The patients completed the
questionnaires at one week before surgery and at one day
before surgery to assess the test-retest reliability of each
instrument. The questionnaires were completed at three
post-operative time-points to measure change and to
assess the stability of change over one-year of follow-up.
The Research Ethics Board of McMaster University and St.
Joseph's Hospital approved this study.
Clinical and demographic measures
In addition to completing the quality of life instruments
(described in detail below), each patient underwent a
physical examination and the baseline information was
recorded. Demographic information including age,
height, and weight was obtained which permitted the cal-
culation of BMI (kg/m2). Other baseline information col-
lected included self-reported bra cup size, diabetes,
history of depression, smoking history, shoulder groov-
ing, shoulder pain, back pain, neck pain, breast pain,
intertrigo, and history of headaches.
Generic utility instruments: HUI
The HUI is a well-known health status and quality of life
assessment instrument developed as an indirect method
of measuring utilities (preferences) in clinical trials and
other studies [25-28]. The HUI is a comprehensive, relia-
ble, responsive, and valid multi-attribute utility instru-
ment [25-28]. Responses to the questionnaire are
converted using standard algorithms to levels of the
Health Utilities Index Mark 2 (HUI2) and Mark 3 (HUI3)
multi-attribute health status classification systems. The
attribute levels are combined with published scoring func-
tions to calculate utility scores of overall HRQL.
The HUI2 and HUI3 health status classification systems
are complementary. Together they provide descriptive
measures of ability or disability for health-state attributes,
and descriptions of comprehensive health status [28]. The
HUI2 is composed of seven attributes or dimensions
which are sensation, mobility, emotion, cognition, self-
care, pain, and fertility [25-28]. The HUI3 is composed of
eight attributes or dimensions: vision, hearing, speech,
ambulation, dexterity, emotion, cognition, and pain with
five to six levels per attribute [25-28]. A seven-element
vector describes the HUI2 comprehensive health state of a
patient. Standard HUI questionnaires do not assess HUI2
fertility and, for the purposes of calculating overall HRQL,
patients in this study were assumed to have no problems
with their fertility. An eight-element vector, one level for
each attribute (domain or dimension) of health, describes
the HUI3 comprehensive health state for a patient or
group of patients. The levels range from highly impaired
to normal. For overall health status, the HUI2 and HUI3
utility scales of HRQL are defined such that dead = 0.00
and perfect health = 1.00. The HUI2 describes 24,000
unique health states and the HUI3 describes 972,000
unique health states that are obtained from factorials of
the number of levels in each attribute.
Utilities derived from responses to HUI questionnaires
may be used to calculate quality adjusted life years
(QALYs). QALYs are the measure of effectiveness in cost-
utility analysis, a special type of cost-effectiveness analysis
for comparing alternative surgical interventions [25-
28,31].
Generic health profile: SF-36
The SF-36 is a multi-purpose, short-form health survey
with 36 questions [29]. It is a generic measure, as opposed
to one that targets a specific age, disease, or treatment
group. Accordingly, the SF-36 has proven useful in surveys
of general and specific populations, comparing the rela-
tive burden of diseases, and in differentiating the health
benefits produced by a wide range of different treatments
[29]. The experience to date with the SF-36 has been doc-
umented in nearly 4,000 publications; citations for those
published in 1988 through 2000 are documented in a
bibliography covering the SF-36 and other instruments in
the "SF" family of tools [29].
The SF-36 contains multi-function item scales to measure
eight domains: physical function (10 items); role physical
(4 items); bodily pain (2 items); general health (5 items);
vitality (4 items); social functioning (2 items); role emo-
tional (4 items); and mental health (5 items) [29]. The
two summary measures of the SF-36 are the physical com-
ponent summary and the mental component summary
[29]. The scores for the multi-function item scales and the
summary measures of the SF-36 vary from zero to 100,
with 100 being the best possible score and zero being the
lowest possible score [29].
Disease (condition) specific quality of life instruments: 
MBSRQ-AS and BRSQ
The MBSRQ is a well-validated self-report inventory for
the assessment of body image [30]. Body image is con-
ceived as one's attitudinal dispositions toward the physi-
cal self. As attitudes, these dispositions include evaluative,
cognitive, and behavioral components. The physical self
encompasses not only one's physical appearance but also
the body's competence or fitness and its biological integ-
rity or health/illness. The MBSRQ is a 69-item self-report
inventory for the assessment of self-attitudinal aspects of
the body-image construct [30]. The MBSRQ is intended
for use with adults and adolescents over the age of 15
years [30]. Two forms of the MBSRQ are available, the full
version and the MBSRQ-Appearance Scales (MBSRQ-AS).
The full, 69-item version consists of seven factor sub-
scales: 1) appearance evaluation, 2) appearance orienta-
tion, 3) fitness evaluation, 4) fitness orientation, 5) healthHealth and Quality of Life Outcomes 2005, 3:44 http://www.hqlo.com/content/3/1/44
Page 4 of 10
(page number not for citation purposes)
evaluation, 6) health orientation, and 7) illness orienta-
tion [30]. There are also three multi-item subscales: 1) the
body areas satisfaction scale (BASS), 2) the overweight
pre-occupation scales, and 3) the self-classified weight
scale [30].
In this study, the shorter version of the MBSRQ-AS was
used and only the appearance evaluation subscale was
used, because we were concerned with measuring body
image. Scores vary from one to five. A high score indicates
emphasis on one's looks, attention to one's appearance,
and engaging in extensive grooming behaviours. A low
score indicates apathy about one's appearance, one's
looks are not especially important, and not expending
much effort to "look good". High scorers feel mostly pos-
itive and satisfied with their appearance; low scorers have
a general unhappiness with their physical appearance
[30].
The BRSQ lists 13 breast related symptoms and the
respondent indicates how much of the time she has the
symptoms [7,24]. From this questionnaire, two scores are
derived. The first score is the breast symptom summary
score (BSS score), which is calculated by taking the mean
scores of all 13 items. The BSS score varies from zero to
100, with a high score corresponding to fewer and less
severe breast symptoms. For the second score, seven items
of the 13-item scale are used to provide the physical symp-
tom count. However, we did not tabulate the physical
symptom count for this prospective study, as we were only
interested in the overall BRSQ summary score (BSS score).
The BRSQ has been validated and has demonstrated good
test-retest reliability [7,8,24].
Scoring of the questionnaires
Scores for the HUI2, the HUI3, and the SF-36 were gener-
ated according to algorithms from the developers [32] and
the SF-36® Health Survey Manual & Interpretation Guide,
[33] respectively. The MBSRQ-AS and the BRSQ were
scored according to the algorithm provided by Cash et al
and Kerrigan et al, respectively [7,24,30].
Reliability and validity testing of the HRQL questionnaires
A measure is reliable if it is sound and dependable. Relia-
bility is assessed by tests of repeatability or reproducibil-
ity. Reliability is often assessed in terms of agreement
between intra-subject test-retest measurements and inter-
assessor measurements [34]. There are various ways of
assessing reliability of a measure [35]. These can be classi-
fied as inter-observer reliability (degree of agreement
between different observers) and intra-observer or test-
retest reliability (agreement between observations made
by the same observer). An intraclass correlation coeffi-
cient (ICC) is used in this paper as a statistical measure of
agreement for assessing test-retest reliability.
To estimate test-retest reliability, the same HRQL instru-
ment is completed by the same patient on two different
occasions. The assumption is that there would be no
change in the scorers if there is no substantial change in
health status of the patient being measured between the
two occasions. The test-retest reliability of patients'
responses is extremely important as we were most inter-
ested in determining that the difference in scores, between
pre- and post-operative times reflected a real change in the
patient's health is a result of the surgical intervention. If
patient reporting is not reliable then one cannot truly cap-
ture the change in health status in patients using HRQL
questionnaires.
The reliability of a test is indicated by the reliability coef-
ficient. Reliability is expressed as a number ranging
between zero and one; as it approaches zero there is lower
reliability and a reliability coefficient close to one indi-
cates higher reliability. In other words, the larger a relia-
bility coefficient is, the more repeatable or reliable the test
scores. General guidelines exist for interpreting reliability
coefficients. A reliability coefficient value of 0.90 and
greater is said to be excellent; a reliability coefficient value
of 0.80 to 0.89 is good; a reliability coefficient value of
0.70 to 0.79 is adequate; and a reliability coefficient value
below 0.70 may have limited applicability [36].
The validity and reliability of the HUI2, HUI3, and the SF-
36 instruments have been demonstrated in various popu-
lations [25-29]. The MBSRQ has been validated and some
reliability testing has been completed [30]. The BRSQ has
been tested for face validity and has undergone test-retest
reliability [7,24].
In this study we assessed the test-retest reliability of the
HUI2, the HUI3, the MBSRQ-AS, and the BRSQ in
patients diagnosed with breast hypertrophy prior to
undergoing breast reduction mammoplasty. We did not
assess the test-retest reliability of the SF-36 because we
had used the four-week recall period for the SF-36. This
study also provides some evidence about the concurrent
validity of the BRSQ.
Responsiveness of the HRQL questionnaires
We used two generic and two disease (condition) specific
instruments in this prospective study. Generic health sta-
tus measures seek a broad perspective that is not specifi-
cally related to the restricted score of the HRQL of a
specific disease or condition. Using a generic instrument
has the advantage of allowing comparisons of health sta-
tus to be made across different diseases and health states
[37]. Disease (condition) specific measures focus on the
disease or condition being studied, allowing greater sensi-
tivity to intervention-related change compared to generic
measures [37]. When deciding to use a generic instrumentHealth and Quality of Life Outcomes 2005, 3:44 http://www.hqlo.com/content/3/1/44
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or a disease (condition) specific instrument to measure
HRQL, it is important to consider the responsiveness of a
HRQL instrument [37]. There are two major aspects of
responsiveness, internal responsiveness and external
responsiveness [38]. Internal responsiveness characterizes
the ability of a measure to change over a pre-specified
timeframe, whereas external responsiveness reflects the
extent to which change in a measure relates to a corre-
sponding change in a reference measure of clinical or
health status [38]. This study focuses on internal
responsiveness.
The effect size index is a statistical measure that can be
used as an indicator of internal responsiveness. The math-
ematical formula for the effect size is the difference (∆) of
mean follow-up assessment scores minus mean baseline
assessment score divided by the standard deviation of the
baseline scores [39]. Our baseline was one-day before sur-
gery and follow-up was six months after surgery. Accord-
ing to the well-known thresholds set by Cohen, an effect
size of less than 0.20 can be considered trivial, an effect
size between 0.20 and 0.50 can be considered small, an
effect size between 0.50 and 0.80 can be considered mod-
erate, and an effect size greater than 0.80 is considered
large [40]. The standardized response mean (SRM) is the
mean change scores divided by the standard deviation of
the change scores [40].
Minimum Important Differences (MID)
The minimum important difference is a measure of clini-
cally important or relevant change in health [37]. In other
words, the minimum clinically important difference is the
minimum level of change of an outcome measure that is
considered to be clinically relevant. Drummond reported
that differences of 0.03 or greater in mean utility scores
were definitely clinically important [41]. This is supported
by Grootendorst et al and Horsman et al, who reported
that a difference in mean overall HUI scores of 0.03 or
more should be considered as clinically important, and by
Samsa et al who indicate minimal clinically important dif-
ferences of HUI overall scores are between 0.02 to 0.04
[28,42,43]. Differences in mean HUI single-attribute util-
ity scores of 0.05 or greater are considered clinically
important [28].
There is no rule for determining what constitutes the min-
imum clinically important difference on the SF-36 sub-
scales [14]. A 10-point change in scores has been
suggested as a rule of thumb to apply on 100-point qual-
ity of life scales [44]. Minimum important differences
have not been reported for the MBSRQ-AS and the BSS
score.
Correlation analyses for assessing redundancy among 
instruments and concurrent validity of BSS score
Correlation analysis will provide information about the
degree of redundancy from measurements using various
instruments and evidence about the concurrent validity of
the BSS score. Concurrent validity is a form of construct
validity [35]. With concurrent validity, a new scale is cor-
related with another measure thought to be measuring the
same construct and both are administered at the same
time points [35].
In the current study, the change score of each question-
naire was correlated with the change score of the other
questionnaires to assess the degree of redundancy among
measures and to assess the concurrent validity of the BSS
score. We expected all of the change scores to be positively
correlated with each other because they are all scored in a
positive direction, measuring improvement.
Statistical analyses
The patient characteristics were described using frequency
distributions and means. The ICC of test-retest reliability
was computed using data from one week prior to surgery
(time one) and one day prior to surgery (time two) for
each HRQL instrument named above. To measure respon-
siveness, effect size, and standardized response means
[39] were calculated for each of the HRQL instruments
(HUI2, HUI3, SF-36, MBSRQ-AS, and BRSQ) from one-
day before surgery (time two) to six-months after surgery
(time four). The Pearson correlation coefficient was calcu-
lated using the change score from baseline (one-day
before surgery, time two) to six-months after surgery (time
four) to assess concurrent validity among the HRQL
instruments used in this study. The six-month follow-up
was used in the above analyses because there was a higher
completion rate than the 12-month follow-up. All statisti-
cal analyses were performed using the SPSS statistical soft-
ware (version 13.01).
Results
Completion rates
Fifty-two consecutive patients initially consented to par-
ticipate in the study. The first patient was enrolled in April
2001 and the last patient was enrolled in May 2002. Of
the 52 patients who had initially agreed to participate, 49
patients completed the baseline assessment. Patients did
not complete the study for various reasons. One patient
could not sufficiently understand English to complete the
questionnaires, another patient cancelled her surgery after
it had been booked, and one patient decided not to par-
ticipate. Although 49 patients completed the baseline
assessment, some patients did not return their HRQL
questionnaires at all time-points despite several telephone
calls and mailings (Table 1).Health and Quality of Life Outcomes 2005, 3:44 http://www.hqlo.com/content/3/1/44
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Clinical and demographic information
The mean age of the patients was 38 years (minimum 20
years; maximum 68 years). The mean BMI was 30.9 kg/m2
(minimum 21.8 kg/m2; maximum 49.5 kg/m2). Self-
reported bra cup sizes ranged from D to H, with 65 per-
cent of the patients having a cup size of DD. Eighteen per-
cent of patients had a history of depression, eight percent
experienced frequent headaches, and 12 percent were
smokers. Prior to surgery, all of the patients experienced
neck pain, 94 percent experienced back pain, 53 percent
experienced shoulder grooving, 45 percent experienced
shoulder pain, 14 percent had breast pain, and 39 percent
had intertrigo. The mean tissue resection weight for the
left breast was 757.8 grams and the mean tissue resection
weight for the right breast was 822.6 grams.
Test-Rest reliability
The computed ICC for the HUI2 was 0.86, the HUI3 was
0.84, the MBSRQ-AS was 0.85, and BSS score was 0.87.
The HUI2, the HUI3, the BMSRQ-AS, and the BSS score all
demonstrated good test-retest reliability.
Responsiveness
The responsiveness of each instrument is shown in Table
2. The SF-36 physical summary score, the MBSRQ-AS, and
the BSS score had a large effect size, therefore, demonstrat-
ing high responsiveness. The SF-36 mental component
summary and the HUI3 had a moderate effect size and the
HUI2 had a small effect size. The SF-36 mental compo-
nent summary, the HUI2, and the HUI3 had somewhat of
a lower responsiveness than the other HRQL instruments
used in this study. The standard response means for the
measures are of the same magnitude as the effect size.
Minimally Important Differences (MID)
In the current study, the difference identified between the
baseline (the day before surgery) and at six-months after
surgery was 0.06 for the HUI2 which is twice the minimal
important difference identified by Horseman et al [28]
(Table 2). For the HUI3, the observed difference was four
times the minimal important difference identified above
(Table 2). We observed a 10 point increase in the SF-36
physical component summary, which is considered to be
of clinical importance (Table 2) [14,44]. However, we did
not observe a clinically important increase in the SF-36
mental component summary. The difference observed for
the score of the MBSRQ-AS and the BSS score from base-
line to six months after surgery was 0.86 and 45.05,
respectively (Table 2). Since an effect size of two or more
is considered statistically significant (based on the stand-
Table 1: Number of patients who completed each HRQL instrument at each time point
Time Point HUI2 and HUI3 SF-36 MBSRQ-AS BSS Score
1 Week Pre-Op (Time 1) 48 48 47 49
1 Day Pre-Op (Time 2) 47 46 48 49
1 Month Post-Op (Time 3) 42 42 43 44
6 Months Post-Op Time 4 43 40 41 43
1  Y e a r  P o s t - O p  T i m e  5 3 23 03 03 3
HUI2 = Health Utilities Index Mark 2; HUI3 = Health Utilities Index Mark 3; SF-36 = Short-Form 36; MBSRQ-AS = Multidimensional Body Self 
Relations Questionnaire Appearance Assessment; BSS Score = Breast Symptom Summary Score
Table 2: Responsiveness of the HRQL instruments used in this study
Measure Difference SD at Baseline (1-day pre-op) SD ES1  SRM
HUI2 (n = 41) 0.06 0.14 0.14 0.45 0.46
HUI3 (n = 41) 0.12 0.19 0.17 0.63 0.67
SF-36 (Physical) (n = 37) 10.16 8.43 7.45 1.21 1.36
SF-36 (Mental) (n = 37) 7.46 11.75 12.63 0.63 0.59
MBSRQ-AS (n = 40) 0.86 0.65 0.70 1.32 1.23
BSS Score (n = 41) 45.05 13.15 13.74 3.43 3.28
HUI2 = Health Utilities Index Mark 2; HUI3 = Health Utilities Index Mark 3; SF-36 = Short-Form 36; MBSRQ-AS = Multidimensional Body Self 
Relations Questionnaire Appearance Assessment; BSS Score = Breast Symptom Summary Score; SD= Standard Deviation; ES1 = Effect Size (based 
on Cohen, 1988); SRM = Standardized Response Mean; SRM = ∆/SD(∆)
ES1 = ∆ / SD at baseline; Difference (∆) = mean score at 6 month assessment minus mean score at baseline.
* n's reflect the number of patients who have completed the measure at both time-points (baseline and six months) and hence the difference in 
numbers from Table 1.Health and Quality of Life Outcomes 2005, 3:44 http://www.hqlo.com/content/3/1/44
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ardized response mean), we believe that this change is
clinically important and should be further investigated in
other populations.
Assessing redundancy among measures and concurrent 
validity of the BSS score
The Pearson's correlations between changes in pairs of
HRQL scores are presented in Table 3. Five of the 15 cor-
relations are statistically significant. The HUI2 and HUI3
scores are significantly positively correlated with each
other as expected, but scores from HUI2 and HUI3 are not
significantly correlated with scores from any other meas-
ures. The BSS scores are positively correlated with both SF-
36 physical component summary and MBSRQ-AS scores.
The MBSRQ-AS scores are positively correlated with the
SF-36 mental component summary. The SF-36 physical
component summary and the SF-36 mental component
summary are negatively correlated. Moderate or better
associations were observed for HUI2 emotion with SF-36
mental component summary (r = 0.489, p = 0.003) and
MBSRQ-AS (r = 0.618, p < 0.001), for the HUI3 emotion
with SF-36 mental component summary (r = 0.501, p =
0.002), and for HUI3 pain with SF-36 physical compo-
nent summary (r = 0.412, p = 0.013).
Discussion
This study included patients with the diagnosis of breast
hypertrophy who had obtained government approval for
reduction mammoplasty. In our geographical area
(Ontario, Canada), in contrast to other jurisdictions, for
example, Nova Scotia, Canada [18] and the United States
[19], the approval for provincial coverage for reduction
mammoplasty is almost always granted if the patient has
a bra cup size of D or larger and is experiencing physical
symptoms.
A number of previous studies have reported that women
who suffer from breast hypertrophy frequently present
with heightened body image dissatisfaction [45-48]. In
Canada, when plastic surgeons are faced with lawsuits, it
is most commonly from breast surgery and when they are
sued by patients following a breast reduction surgery it is
usually due to the appearance of the breast or scarring
[49]. Body image is conceived as one's attitudinal disposi-
tions toward the physical self. As attitudes, these disposi-
tions include evaluative, cognitive, and behavioral
components. A study of the preoperative body image con-
cerns of breast reduction patients found increased dissat-
isfaction with both their overall body image and breast
size [46]. In response to their excessive breast size,
Table 3: Correlations between changes in the HRQL scores
HUI3 SF-36 (Physical) SF-36 (Mental) MBSRQ-AS BSS Score
HUI2
Pearson Correlation 0.625** 0.135 0.295 0.317 0.221
p-value (2-tailed) <0.001 0.431 0.081 0.053 0.170
n 4 13 63 63 84 0
HUI3
Pearson Correlation 0.1 2 80 . 2 7 30 . 1 2 70 . 1 9 8
p-value (2-tailed) 0.4 5 80 . 1 0 70 . 4 4 60 . 2 2 2
n 3 63 63 84 0
SF-36 (Physical)
Pearson Correlation -0.515** -0.187 0.359*
p-value (2-tailed) 0.001 0.289 0.029
n 37 34 37
SF-36 (Mental)
Pearson Correlation 0.484** 0.147
p-value (2-tailed) 0.004 0.386
n 34 37
MBSRQ-AS
Pearson Correlation 0.481**
p-value (2-tailed) 0.002
N 40
n's reflect the number of patients who have completed the measure at both time-points (baseline and six months) and hence the difference in 
numbers from Table 1.
** Correlation is significant at the 0.01 level (2 tailed)
* Correlation is significant at the 0.05 level (2 tailed)
HUI2 = Health Utilities Index Mark 2; HUI3 = Health Utilities Index Mark 3; SF-36 = Short-Form 36; MBSRQ-AS = Multidimensional Body Self 
Relations Questionnaire Appearance Assessment; BSS Score = Breast Symptom Summary ScoreHealth and Quality of Life Outcomes 2005, 3:44 http://www.hqlo.com/content/3/1/44
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patients reported extreme embarrassment in public areas
and social settings and significant avoidance of physical
activity [46]. Several previous studies on patients with
breast hypertrophy have used the MBSRQ-AS to measure
body image and have found that women with breast
hypertrophy had low scores on the MBSRQ-AS suggesting
dissatisfaction with their overall body image [7,8,24,46].
Patients completed the HUI2, the HUI3, and the BRAVO
instruments (the SF-36, the MBSRQ-AS, and the BRSQ) at
one week and one day before surgery to measure the test-
retest reliability of each instrument and at one, six, and 12
months after surgery to measure change in HRQL follow-
ing breast reduction mammoplasty. The methodology
used in this prospective study may interest those who
wish to sponsor, design, or implement future HRQL stud-
ies in breast reduction surgery or other areas of plastic
surgery.
Of the 52 patients who had initially agreed to participate,
49 patients completed the baseline assessment. Despite
multiple reminders, 30 patients completed all of the
HRQL questionnaires at the 12-month follow up. This
equates to a compliance rate of 57.7 percent. The response
rate in this study is comparable to response rates obtained
in previous studies on HRQL in patients with breast
hypertrophy. For instance, several authors have reported
response rates ranging from 32.5 percent to 80 percent
[5,11,12,14,16]. For future studies, it may be helpful to
understand why patients may not complete all of the
requirements of a research study. The burden of complet-
ing multiple questionnaires may have limited our rate of
compliance at one year. Patients who withdrew consent
from one multi-centre trial reported interference with
work, lack of time, complicated and cumbersome record
keeping requirements, difficult study medicine regimens,
and difficulty scheduling appointments due to a lack of
flexibility on the part of the study personnel [50]. In the
above study, the matched patients who completed all of
their follow up reported that remuneration, commitment
to finish, and the belief that the study was important
motivated them to fully complete the study [50]. Based on
existing guidelines for self-administered questionnaires,
the questionnaires used in the present study exceeded the
12-page upper limit recommendation [51].
To measure the test-retest reliability of each instrument,
scores were obtained for each instrument using the recom-
mended algorithms and the ICC was computed from
these scores. We found that all HRQL instruments demon-
strated good reliability, which reinforces previous reliabil-
ity testing of the HUI2, HUI3, SF-36, MBSRQ-AS, and BSS
score.
It is extremely important that there is low within-patient
variability in stable patients, relative to the magnitude of
change that is predicted following the intervention, while
answering the various questions on quality of life ques-
tionnaires in surgical outcome studies. Absence of reliable
reporting will reduce the ability of measures to assess the
effectiveness of surgery. For the present study, the one-
week interval (time one and time two) was chosen to
assess patient reporting as it was not long enough for
other adverse events to intervene and change the health
status but appropriate to avoid recall bias.
Marx et al noted that if multiple questionnaires were
administered, each consisting of numerous items, the
effect of memory may be minimized and the effect of
memory may be greater if only a single questionnaire was
used [52]. In the present study, four HRQL questionnaires
were administered, each with multiple questions so the
effect of a patient's memory is likely to be limited, there-
fore not biasing the responses.
The SF-36 physical component summary, the MBSRQ-AS,
and the BSS score showed high responsiveness. The SF-36
mental component summary, the HUI2, and the HUI3
had a lower responsiveness summary statistics than the
other HRQL instruments used in this study but all three
instruments were able to detect clinically important
changes in overall HRQL scores. The HUI3 showed a
moderate effect size and detected a clinically important
reduction in pain scores. All of the statistically significant
correlations are positive except for the SF-36 physical
component summary with the SF-36 mental component
summary. The negative correlation may be a function of
the problem with the algorithms for calculating SF-36
physical and mental component summary scores
described in the published literature including reports by
Simon et al [53] and Cunningham et al [54]. This study
confirms evidence of concurrent validity for the BSS score
as the change in BSS score is highly correlated with the SF-
36 and other HRQL measures [19]. The HUI scores appear
to provide unique information, as they were not corre-
lated with the other measures. There were moderate or
stronger correlations of HUI single-attribute utility scores,
for emotion and pain, with the SF-36 and MBSRQ-AS.
This study demonstrates that patient reporting using the
HUI2, the HUI3, the MBSRQ-AS, and the BSS score are
reliable in a sample of patients diagnosed with breast
hypertrophy who had breast reduction mammoplasty. All
instruments were equally reliable. The HUI is the only
preference-based instrument and it was shown to be
responsive. The two disease (condition) specific instru-
ments were the most responsive of all the HRQL instru-
ments usedHealth and Quality of Life Outcomes 2005, 3:44 http://www.hqlo.com/content/3/1/44
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Having established the reliability and responsiveness of
two generic (HUI and SF-36) instruments and two disease
(condition) specific (MBSRQ-AS and BSS score) instru-
ments, and the concurrent validity of BSS score, the focus
moves onto the clinical and policy implications of the
prospective study by addressing the following question:
Can the improvement in HRQL derived from breast
reduction surgery be measured quantitatively? Research is
underway to address four specific issues: 1) identifying
health attributes affected most frequently in breast hyper-
trophy patients and describing the extent of the observed
morbidity; 2) assessing the health status and HRQL of
patients in short, intermediate, and long time periods
after reduction mammoplasty (i.e. one, six, and 12
months); 3) determining if there is a relationship between
tissue resection weight and changes in health status and
HRQL; and 4) determining if there is a relationship BMI
and changes in health status and HRQL to address the
ongoing BMI discrimination by third party payers.
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